Enovis Corporation 10-Q Summary
Business Context and Reporting Period
This unaudited Form 10-Q covers the three months ended April 1, 2022, with comparative results for the three months ended April 2, 2021. The company was formerly Colfax Corporation and operated through Fabrication Technology and Medical Technology segments during the reported quarter.
On April 4, 2022, immediately after the reporting period, the company completed the tax-free separation of its Fabrication Technology business into ESAB Corporation, retained 10% of ESAB, changed its name to Enovis Corporation, and began trading under the symbol ENOV. Historical results in this filing still include both businesses; Fabrication Technology is expected to be presented as discontinued operations beginning in the second quarter of 2022.
Financial Highlights
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Net sales | $1,023.4 million | $879.2 million | Up 16.4% |
| Gross profit | $430.2 million | $371.1 million | Up 15.9% |
| Gross margin | 42.0% | 42.2% | Down 20 basis points |
| Operating income | $53.1 million | $61.3 million | Down 13.4% |
| Operating margin | 5.2% | 7.0% | Down 180 basis points |
| Net income from continuing operations | $19.4 million | $27.7 million | Down 30.2% |
| Net income attributable to Enovis | $15.1 million | $19.1 million | Down 21.0% |
| Diluted earnings per share, continuing operations | $0.33 | $0.56 | Down $0.23 |
| Adjusted EBITA | $129.0 million | $107.1 million | Up 20.4% |
| Adjusted EBITA margin | 12.6% | 12.2% | Up 40 basis points |
Loss from discontinued operations was $3.1 million in Q1 2022 versus $7.5 million in Q1 2021. Consolidated net income was $16.3 million versus $20.2 million in the prior-year quarter.
- Fabrication Technology sales were $647.9 million, up from $568.1 million; segment operating income was $95.5 million versus $82.3 million.
- Medical Technology sales were $375.5 million, up from $311.1 million; segment operating income was a loss of $0.1 million versus income of $2.2 million.
- Strategic transaction costs increased to $21.4 million from $1.4 million, primarily because of Separation-related costs.
- The effective tax rate rose to 49.1% from 22.2%, reflecting withholding taxes, taxable foreign exchange gains, U.S. taxation of international operations, nondeductible expenses, and discrete quarterly items.
Cash Flow, Balance Sheet, Debt and Liquidity
- Operating cash flow was negative $14.4 million, compared with positive $84.4 million in Q1 2021. The decline primarily reflected $61.9 million of working-capital outflows, higher inventory and receivables, Separation payments of $7.9 million, and the absence of a $36.0 million prior-year tax refund.
- Capital expenditures and intangible purchases were $24.1 million. Acquisitions and investments used $13.8 million, compared with $103.5 million in the prior-year period.
- Cash and cash equivalents were $661.5 million at April 1, 2022, down from $719.4 million at December 31, 2021.
- Total debt was $2.070 billion at April 1, 2022, compared with $2.087 billion at year-end 2021. Current debt was $422.3 million and long-term debt was $1.648 billion.
- Before the Separation, $375 million remained available under the prior revolving facility, and the company was in compliance with its debt covenants. Management stated that available liquidity was adequate for the next twelve months.
- The new post-Separation credit agreement provides a $900 million revolving facility maturing in 2027 and a $450 million term loan maturing in 2023. The agreement includes leverage and interest-coverage covenants.
Material Changes Versus the Prior Comparable Period
- Sales growth reflected $124.5 million from existing businesses and $45.6 million from acquisitions, partly offset by a $25.9 million unfavorable foreign-currency impact.
- Gross profit increased, but gross margin narrowed because inflation in materials, logistics and other costs partly offset pricing, volume and mix benefits.
- Operating income and GAAP earnings declined because of higher Separation costs, acquisition-related expenses, restructuring charges, increased selling, general and administrative costs, and the higher tax rate.
- Adjusted EBITA improved due to stronger volumes and sales growth, despite supply-chain, logistics and inflationary pressures.
- Medical Technology sales benefited from acquisitions, particularly in Reconstructive products, but segment profitability was pressured by integration costs, acquisition-related amortization, MDR costs and the dilutive effect of recent acquisitions.
- The tangible equity units mandatorily converted during the quarter, resulting in approximately 1.7 million additional common shares.
Guidance, Outlook, Risks and Unusual Items
- The filing does not provide clear quantitative full-year revenue, earnings or margin guidance.
- Management expects ongoing requirements for working capital, acquisitions, Separation costs, capital expenditures, restructuring, debt service and principal repayments.
- Management expects approximately $17 million of net debt-extinguishment losses in Q2 2022, including redemption premiums and noncash write-offs, plus approximately $7 million of additional costs related to the new credit facility and extinguishment of the prior facility.
- Enovis intends to divest its retained 10% ESAB stake in a tax-efficient exchange for debt no later than twelve months after the Separation. The stake was estimated at approximately $300 million based on ESAB's initial opening share price and will be marked to market.
- Key risks include failure to realize Separation benefits, potential tax liabilities or indemnification obligations associated with the Separation, supply-chain constraints, inflation, labor shortages, logistics disruption, COVID-19 effects, foreign-currency volatility, commodity prices, acquisitions and integration, cybersecurity, regulatory compliance, product liability, and the Russia-Ukraine conflict.
- Asbestos contingencies remain material. At April 1, 2022, accrued and long-term asbestos liabilities totaled approximately $288.6 million, partially offset by insurance assets and receivables. Management cautioned that actual claims, recoveries and liabilities could differ materially from recorded amounts.
Important Facts for Investors to Verify
- Post-Separation financial statements and segment presentation, including the classification of Fabrication Technology as discontinued operations.
- The final amount, maturity profile, interest rates and covenant compliance under the new Enovis credit facilities.
- The actual Q2 2022 debt-extinguishment and Separation-related charges compared with management's estimates.
- The timing, valuation and tax treatment of the retained ESAB shares and intended debt exchange.
- Whether working-capital outflows, elevated inventory, supply-chain costs and inflation persist.
- The effective tax rate and whether the unusually high Q1 rate normalizes in subsequent periods.
- Potential asbestos, tax, indemnification and other contingent liabilities following the Separation.